Hims & Hers Health, Inc. (NYSE:HIMS) Insider Michael Chi Sells 17,303 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,303 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $48.14, for a total value of $832,966.42. Following the sale, the insider now directly owns 193,601 shares in the company, valued at $9,319,952.14. This trade represents a 8.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Chi also recently made the following trade(s):

• On Monday, February 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $43.28, for a total value of $314,169.52.
• On Friday, January 24th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.00, for a total value of $536,424.00.
• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.07, for a total value of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.97, for a total value of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $39.95 on Wednesday. Hims & Hers Health, Inc. has a 1-year low of $9.67 and a 1-year high of $72.98. The stock’s 50-day moving average is $35.62 and its 200 day moving average is $26.25. The company has a market cap of $8.73 billion, a P/E ratio of 90.79 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Crewe Advisors LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at about $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on HIMS shares. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday. Canaccord Genuity Group increased their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Needham & Company LLC increased their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $33.40.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.